RxDoctor Payments Data

Pramod Pinnamaneni, MD

Internal Medicine · Lufkin, TXNPI 1740570274

Payments from drug & device makers

$10,274in general payments, 2019–2025

Across 323 payments — averaging $31.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • AstraZeneca$655
  • GSK$455
  • Daiichi Sankyo Inc.$395
  • Astellas Pharma US Inc$392
  • Pfizer$368
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$1,57515%
  • Food & beverage$5,98358%
  • Education$9379%
  • Other$1,78017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,274 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,815,786
Medicare patients
272
Services billed
120,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide52$724,252
RevlimidLenalidomide29$556,912
ErleadaApalutamide37$521,337
TagrissoOsimertinib Mesylate15$294,652
ImbruvicaIbrutinib18$285,173
LonsurfTrifluridine/Tipiracil Hcl12$242,512
IbrancePalbociclib12$181,816
XtandiEnzalutamide12$168,910
NinlaroIxazomib Citrate11$165,689
Abiraterone Acetate32$60,935
Exemestane36$4,160
Anastrozole112$1,667
Hydroxyurea66$1,402
Ondansetron Hcl111$1,048
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$242$556,91229 claims
Johnson & JohnsonErleada$90$521,33737 claims
AstraZenecaTagrisso$655$294,65215 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$249$285,17318 claims
Taiho Oncology, Inc.Lonsurf$109$242,51212 claims
PfizerIbrance$368$181,81612 claims
Astellas Pharma US IncXtandi$392$168,91012 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$106$165,68911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →